Contact Dermatitis - Pipeline Review, H2 2022
Contact Dermatitis - Pipeline Review, H2 2022
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H2 2022, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.
Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis - Pipeline Review, H2 2022, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 3 respectively. Similarly, the Universities portfolio in Phase III stages comprises 1 molecules, respectively.
Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Brickell Biotech Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Edesa Biotech Inc
Hapten Sciences Inc
ILiAD Biotechnologies LLC
Signum Dermalogix Inc
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Contact Dermatitis - Overview
Contact Dermatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Contact Dermatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Contact Dermatitis - Companies Involved in Therapeutics Development
Brickell Biotech Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Edesa Biotech Inc
Hapten Sciences Inc
ILiAD Biotechnologies LLC
Signum Dermalogix Inc
Contact Dermatitis - Drug Profiles
BBI-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPT-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-1322 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WOL-071007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Contact Dermatitis - Dormant Projects
Contact Dermatitis - Discontinued Products
Contact Dermatitis - Product Development Milestones
Featured News & Press Releases
Dec 03, 2019: Edesa Biotech reports positive healthy volunteer data and expands Phase 2b Dermatitis Study to patients with Facial Lesions
Oct 21, 2019: Edesa Biotech enrolls first patient in phase 2b dermatitis study
Jul 25, 2019: Edesa Biotech completes manufacturing for upcoming dermatitis study
Jun 20, 2019: Edesa Biotech receives approval to proceed with U.S. clinical study
Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerList of Tables
Number of Products under Development for Contact Dermatitis, H2 2022
Number of Products under Development by Companies, H2 2022
Number of Products under Development by Universities/Institutes, H2 2022
Products under Development by Companies, H2 2022
Products under Development by Universities/Institutes, H2 2022
Number of Products by Stage and Target, H2 2022
Number of Products by Stage and Mechanism of Action, H2 2022
Number of Products by Stage and Route of Administration, H2 2022
Number of Products by Stage and Molecule Type, H2 2022
Contact Dermatitis - Pipeline by Brickell Biotech Inc, H2 2022
Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2022
Contact Dermatitis - Pipeline by Edesa Biotech Inc, H2 2022
Contact Dermatitis - Pipeline by Hapten Sciences Inc, H2 2022
Contact Dermatitis - Pipeline by ILiAD Biotechnologies LLC, H2 2022
Contact Dermatitis - Pipeline by Signum Dermalogix Inc, H2 2022
Contact Dermatitis - Dormant Projects, H2 2022
Contact Dermatitis - Discontinued Products, H2 2022List of Figures
Number of Products under Development for Contact Dermatitis, H2 2022
Number of Products under Development by Companies, H2 2022
Number of Products by Targets, H2 2022
Number of Products by Stage and Targets, H2 2022
Number of Products by Mechanism of Actions, H2 2022
Number of Products by Stage and Mechanism of Actions, H2 2022
Number of Products by Routes of Administration, H2 2022
Number of Products by Stage and Routes of Administration, H2 2022
Number of Products by Molecule Types, H2 2022
Number of Products by Stage and Molecule Types, H2 2022
Research Methodology
The research study released with title "Contact Dermatitis - Pipeline Review, H2 2022" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Contact Dermatitis Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Contact Dermatitis Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Contact Dermatitis Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Contact Dermatitis Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Contact Dermatitis - Pipeline Review, H2 2022" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
